<DOC>
	<DOC>NCT01657019</DOC>
	<brief_summary>To evaluate the safety and tolerability of SPD489 administered as a daily morning dose (50 or 70mg) in the treatment of moderate to severe binge eating disorder (BED) in adults</brief_summary>
	<brief_title>Open Label Extension in Adults With Binge Eating Disorder (BED)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Feeding and Eating Disorders</mesh_term>
	<mesh_term>Binge-Eating Disorder</mesh_term>
	<mesh_term>Bulimia</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>Inclusion criteria: 1. Completion of an antecedent SPD489 BED Doubleblind Study 2. Subject meets the following Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision (DSMIVTR) criteria for a diagnosis of BED 3. Subject has a body mass index (BMI) of &gt; or =18 and &lt; or =45 Exclusion criteria: 1. Subject has concurrent symptoms of bulimia nervosa or anorexia nervosa. 2. Subject is considered a suicide risk or risk to harm others</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>